Cowen Starts Sophia Genetics SA (SOPH) at Outperform

Cowen analyst Doug Schenkel initiates coverage on Sophia Genetics SA (NASDAQ: SOPH) with a Outperform rating.

The analyst comments "SOPH is an emerging leader in the decentralization of comprehensive genetic testing; the company also seeks to expand into adjacencies, such as proteomics. Via its unique DDM platform, the company has emerged as an early leader with a global network of customers. We believe there are 5 core pillars of value creation over the long term (discussed herein). We initiate with an Outperform rating."

For an analyst ratings summary and ratings history on Sophia Genetics SA click here. For more ratings news on Sophia Genetics SA click here.

Shares of Sophia Genetics SA closed at $18.09 yesterday.

You May Also Be Interested In

• B.Riley Starts Suncrete Inc (RMIX) at Buy
• Barclays Starts SAB Biotherapeutics (SABS) at Overweight
• AmerX Starts WidePoint Corp (WYY) at Buy